Surrozen is discovering and developing new drug candidates to treat injury and disease by targeting the Wnt pathway. The Wnt pathway plays a critical role in development processes, stem cell maintenance and tissue regeneration. Combining their understanding of the Wnt pathway with advanced antibody engineering strategies, Surrozen is designing tissue-specific antibodies that engage the body’s own biological repair mechanisms to regenerate tissue. With pharmaceutical properties, Surrozen’s platform has the potential to overcome many of the current limitations of regenerative medicines.

Surrozen

Exec. Director/Vice President, Clinical Development

 HRMY: 3 Biotech Gems to Keep on Your Radar 

Wnt-focused Surrozen bags $50M to push regenerative ...

 Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis 

Ding, et al., Therapeutic blood-brain barrier modulation and stroke treatment by a bioengineered FZD4-selective WNT surrogate in mice, Nat Commun, 14, 2947 (2023)

Zhang, et al. Tissue-targeted R-spondin mimetics for liver regeneration. Sci Rep, 10(1):13951 (2020)

Wnt-focused Surrozen bags $50M to push regenerative medicine for liver disease - Fierce Biotech

Sampathkumar, et al., Targeted protein degradation systems to enhance Wnt signaling, eLife,  13:RP93908 (2024)

 Why Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday? - Surrozen (NASDAQ:SRZN) 

 Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference 

 Surrozen stops IBD program due to dose concerns and competition 

Surrozen Pauses Phase I Trial Following Liver Enzyme Elevations - BioSpace

Surrozen Provides Third Quarter 2024 Financial Results and Business Update - The Manila Times

 Surrozen Inc trading resumes 

 Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway 

 Surrozen Inc trading halted, news pending 

Surrozen stock soars to 52-week high, hits $16.35 - Investing.com

The Column Group's biotech taps Surrozen for lung disease research pact - Fierce Biotech

Goldman Sachs Group Inc's Strategic Investment in Surrozen Inc - GuruFocus.com

Janda, et al. Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signaling. Nature, 545, 234-237 (2017)

Surrozen Shares Soar on $10M Milestone Payment, Strong Clinical Progress in Q3 - StockTitan

 Surrozen publishes study in 'eLife' on the proprietary SWEETS platform 

Surrozen partners with TCGFB for lung disease therapy By Investing.com - Investing.com Nigeria

 Surrozen announces up to $192.5M private placement of securities priced at-the-market 

Nguyen, et al. SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy. Translational Vision Science & Technology 11, 19 (2022)

 Surrozen cuts inflammatory bowel disease drug as cash, stock drop 

 Age-Related Macular Degeneration Market to Grow Rapidly ... 

 Modulation of wnt signalling in corneal disorders 

 Surrozen Pauses Phase I Trial Following Liver Enzyme Elevations 

 Surrozen to Present at Upcoming Healthcare Investor Conferences 

Boehringer sets sights on Surrozen's preclinical retinal disease asset in $600M deal - Fierce Biotech

 In add-on to eye disease pipeline, Boehringer pays Surrozen to acquire rights to Wnt drug 

 Liver-specific wnt signal enhancing molecules and uses thereof 

Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal - Fierce Biotech

 Surrozen Scientific Founder Roel Nusse, PhD Receives Prestigious Canada Gairdner International Award for Biomedical Research 

 Cell targeting multicomponent polypeptide 

 Wnt-surrogate agents and methods for lacrimal gland regeneration 

 Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules 

Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone - Endpoints News

 Chen, et al. BRAIDing receptors for cell-specific targeting, 12:RP90221, eLife (2024)

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky - Simply Wall St

 Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique ... 

 Surrozen reports positive Phase 1a trial results for liver therapy By Investing.com 

Surrozen (NASDAQ:SRZN) Upgraded by Guggenheim to “Buy” Rating - Defense World

Fowler, et al. Development of selective bispeciﬁc Wnt mimetics for bone loss and repair, Nature Communications (2021)

 Patel, et al. A Wnt mimetic with broad spectrum FZD-specificity decreases fibrosis and improves function in a pulmonary damage model, 25:153, Respiratory Research (2024)

Frizzled sizzles as Surrozen nails down Boehringer deal worth almost $600M - BioWorld Online

Surrozen culls 2 research programs as cash preservation ...

 Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial ... 

 Frizzled sizzles as Surrozen nails down Boehringer deal worth almost $600M 

Xie, et al. Robust Colonic Epithelial Regeneration and Amelioration of Colitis via FZD-Specific Activation of Wnt Signaling. Cellular and Molecular Gastroenterology and Hepatology, 14, 435-464 (2022) 

 Wnt receptor-specific compound and method relating thereto 

Nguyen, et al., Selective Activation of the Wnt-Signaling Pathway as a Novel Therapy for the Treatment of Diabetic Retinopathy and Other Retinal Vascular Diseases, Pharmaceutics 2022, 14(11), 2476 (2022)

StemPoint Capital LP Increases Stake in Surrozen Inc - GuruFocus.com

 Surrozen raises $50M to advance Wnt pathway modulators to the clinic 

Liver enzyme elevations in healthy volunteers prompts soul searching at Surrozen - Fierce Biotech

Hu, et al. Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids, Cell (2018)

Boehringer Ingelheim to advance SZN-413 for retinal diseases - BioWorld Online

 Surrozen's Wnt mimetic antibody improves lung function in mice with pulmonary fibrosis 

 Surrozen Shares Tumble 26% on Securities Purchase Agreement 

Financial Review: Surrozen (NASDAQ:SRZN) & Vericel (NASDAQ:VCEL) - Defense World

Surrozen culls at least 2 research programs to funnel more money toward clinical work - Fierce Biotech

Chen, et al. Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies, 7:88, Antibody Therapeutics (2024)

 Surrozen Commences Phase 1 Study of SZN-1326 In Ulcerative Colitis 

The Column Group biotech taps Surrozen to target lung ...

 Liver enzyme elevations in healthy volunteers prompts soul searching at Surrozen 

Chen et al. Development of Potent, Selective Surrogate WNT Molecules and Their Application in Defining Frizzled Requirements. Cell Chemical Biology, Online, (2020)

Regenerative medicine biotech Surrozen aims for the ...

 Surrozen Shares Rise 7% After License Agreement With Boehringer Ingelheim 

 Surrozen Chooses TransPerfect’s Trial Interactive eClinical Platform for Comprehensive TMF Management 

 Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 

Surrozen stops IBD program due to dose concerns and competition - Fierce Biotech

Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway - BioSpace

 Boehringer sets sights on Surrozen’s preclinical retinal disease asset in $600M deal 

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - Yahoo Finance

 Surrozen Provides Corporate Update on Clinical Programs 

Surrozen's Wnt mimetic antibody improves lung function in mice with pulmonary fibrosis - Fierce Biotech

Surrozen

Business:

Drug notes:

About: